


# Copper-Catalyzed Alkynylation/Cyclization/Isomerization Cascade for Synthesis of 1,2-Dihydrobenzofuro[3,2-*b*]pyridines and Benzofuro[3,2-*b*]pyridines

Huan-Ping Xie,<sup>†,‡</sup> Lei Sun,<sup>†</sup> Bo Wu,<sup>†</sup> and Yong-Gui Zhou<sup>\*,†,§</sup><sup>†</sup>State Key Laboratory of Catalysis, Dalian Institute of Chemical Physics, Chinese Academy of Sciences, Dalian 116023, P. R. China<sup>‡</sup>University of Chinese Academy of Sciences, Beijing 100049, P. R. China<sup>§</sup>State Key Laboratory of Organometallic Chemistry, Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences, Shanghai 200032, P. R. China

## Supporting Information



**ABSTRACT:** An efficient copper-catalyzed cascade alkynylation/cyclization/isomerization reaction of aurone-derived azadienes with terminal alkynes has been developed, giving a series of 1,2-dihydrobenzofuro[3,2-*b*]pyridines with excellent yields. The obtained 1,2-dihydrobenzofuro[3,2-*b*]pyridines can be conveniently transformed into the corresponding benzofuro[3,2-*b*]pyridines under basic conditions. Additionally, benzofuro[3,2-*b*]pyridines can also be prepared from azadienes and terminal alkynes in a one-pot reaction. The synthetic utility was demonstrated by the synthesis of three bioactive molecules with potent topoisomerase inhibition in high yields. This strategy provides a facile approach to 1,2-dihydrobenzofuro[3,2-*b*]pyridines and benzofuro[3,2-*b*]pyridines.

## INTRODUCTION

The direct and rapid construction of complicated and diversified molecules from easily available starting materials has great importance in synthetic chemistry and industrial processes.<sup>1</sup> In this regard, cascade reactions enable multiple transformations in a single step and provide diverse scaffolds with undoubted benefits involving atom economy, efficiency, and sustainability of resources.<sup>2</sup> Consequently, the development of cascade reactions has attracted considerable attention and been a powerful strategy for the synthesis of various scaffolds and complex natural products.<sup>2,3</sup> Dihydropyridines are ubiquitous structural fragments in a myriad of biologically active molecules, natural products, and synthetic drugs.<sup>4</sup> In particular, 1,2-dihydropyridines are prominent synthetic intermediates to prepare a wide range of organic molecules, such as piperidines, indolizidines, quinolizidines, and isoquinolidines.<sup>5</sup> Due to the prevalence and significance of 1,2-dihydropyridines, various strategies for their construction have been developed, including condensation reactions of amines and carbonyl compounds,<sup>6</sup> partial reduction, or nucleophilic addition to pyridines and pyridinium salts,<sup>7</sup> and pericyclic reactions.<sup>8</sup> Although considerable progress has been achieved, there are still some disadvantages, such as harsh conditions, noble metal catalysts, etc., inhibiting their wide application.

Hence, the development of straightforward and convenient synthesis of 1,2-dihydropyridines is highly desirable.


Aurone-derived azadienes have been recognized as a crucial class of highly reactive intermediates in organic synthesis due to the driving force of aromatization.<sup>9</sup> In the past few years, numerous annulations of aurone-derived azadienes to construct benzofuran-fused heterocyclic compounds have been reported.<sup>9a-h,k-o,s,t</sup> As our contiguous interest in the utilization of azadienes, we previously disclosed the systematic work of asymmetric nucleophilic addition and annulation.<sup>9h-j,r</sup> Considering that copper-catalyzed alkynylation with terminal alkynes is a straightforward and general access to substituted alkynes, we envisioned copper-catalyzed cascade reactions of azadienes and terminal alkynes to give 1,2-dihydrobenzofuro[3,2-*b*]pyridines. The mechanism might be hypothesized as follows. First, copper-catalyzed alkynylation of azadiene produced substituted alkyne **A**. Subsequently, intermediate **A** underwent an intramolecular 6-endo-dig cyclization through the activation of the triple bond with a  $\pi$ -philic metal, delivering 1,4-dihydropyridine **B**. Finally, the isomerization of intermediate **B** afforded 1,2-dihydrobenzofuro[3,2-*b*]pyridines. Herein, we described copper-catalyzed cascade alkynylation/

Received: September 16, 2019

Published: November 8, 2019

cyclization/isomerization reactions of azadienes with terminal alkynes for the synthesis of 1,2-dihydrobenzofuro[3,2-*b*]-pyridines (Scheme 1). The obtained 1,2-dihydrobenzofuro[3,2-*b*]pyridines can be conveniently transformed into the corresponding benzofuro[3,2-*b*]pyridines under basic conditions.

### Scheme 1. Copper-Catalyzed Cascade Reactions for the Synthesis of 1,2-Dihydrobenzofuro[3,2-*b*]pyridines



## RESULTS AND DISCUSSION

To initiate our investigation, azadiene **1a** and phenylacetylene **2a** were chosen as model substrates for condition optimization. Under the catalysis of  $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4/\text{BINAP}$  in tetrahydrofuran at 60 °C, the cascade reaction occurred with a moderate 48% yield in 48 h (Table 1, entry 1). The structure of the product was determined to be 1,2-dihydropyridine derivative **3aa** by X-ray single-crystal diffraction analysis [see Supporting Information (SI)]. Alteration of copper precursors to  $\text{Cu}(\text{OTf})_2$  and  $\text{CuI}$  resulted in a significant decrease in reactivity (Table 1, entries 2 and 3). A series of commercially available ligands were evaluated, and it was found that ligand had an obvious influence. Monophosphorus ligands such as triphenylphosphine **L4** and tricyclohexylphosphine **L5** exhibited low reactivity. Bipyridine ligand **L6** stopped the reaction. Diphosphine ligand XantPhos **L3** was the most efficient ligand, providing the product in 86% yield (Table 1, entries 4–9). The effect of the base was explored. Good yield was obtained with *N,N*-diisopropylethylamine (DIPEA) and moderate yield was achieved with potassium carbonate (Table 1, entries 10 and 11). Subsequently, the effect of solvents was evaluated. 1,4-Dioxane proved to be the most favorable solvent in 96% yield (Table 1, entries 12–14). Notably, the reactivity could be maintained when the catalyst loading was reduced to 5 mol % (Table 1, entry 15). Therefore, the optimal condition was established: using  $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4/\text{XantPhos}$  as the catalyst, triethylamine as the base, and 1,4-dioxane as the solvent to perform the reaction at 60 °C.

With the aforementioned optimal reaction conditions, we turned our attention to the scope of this cascade reaction between azadienes **1** and alkynes **2**. The results are summarized in Scheme 2. In general, the transformation proceeded smoothly, delivering the desired benzofuran-fused 1,2-dihydropyridines **3** in excellent yields. Various aurone-derived azadienes were suitable for the cascade reaction. The steric and electronic properties of the substituents on the aromatic ring had only a marginal effect on yields. For instance, the reaction afforded the target products **3ba** and **3ga** in 93


Table 1. Optimization of Reaction Conditions<sup>a</sup>

entry	[Cu]	L	solvent	yield (%) <sup>b</sup>
1	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L1	THF	48
2	$\text{Cu}(\text{OTf})_2$	L1	THF	12
3	$\text{CuI}$	L1	THF	17
4	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L2	THF	25
5	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L3	THF	86
6	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L4	THF	12
7	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L5	THF	37
8	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L6	THF	
9	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$		THF	
10 <sup>c</sup>	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L3	THF	84
11 <sup>d</sup>	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L3	THF	32
12	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L3	toluene	94
13	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L3	1,4-dioxane	96
14	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L3	acetonitrile	7
15 <sup>e</sup>	$\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$	L3	1,4-dioxane	97

<sup>a</sup>Conditions: **1a** (0.10 mmol), **2a** (0.30 mmol), [Cu] (10 mol %), L (10 mol %), while **L4** and **L5** were used in 20 mol %, solvent (1.5 mL), Et<sub>3</sub>N (0.10 mmol), 60 °C, 48 h. <sup>b</sup>Isolated yields. <sup>c</sup>DIPEA (0.10 mmol) was used. <sup>d</sup> $\text{K}_2\text{CO}_3$  (0.10 mmol) was used. <sup>e</sup>Catalyst loading was reduced to 5 mol %.


and 96% yield, respectively. For azadienes with a methyl substituent at the 5- or 6-position of the benzofuryl ring, products **3ka** and **3la** were afforded in 96 and 98% yield, respectively. Sulfonylimines **1m** and **1n** were transformed successfully with moderate to good yields. Additionally, azadiene containing a trifluoromethyl substituent performed the cascade reaction smoothly, offering the target product **3oa** in 57% yield. Furthermore, a series of terminal alkynes were evaluated. Excellent yields were observed for substituted phenylacetylenes as well as terminal alkyne bearing thienyl functionality. When a strong electron-withdrawing group such as trifluoromethyl was introduced into terminal alkyne, only moderate yield was obtained. The yield decreased dramatically for terminal alkynes bearing alkyl substituents. Only 11% yield was achieved with *tert*-butylacetylene, and the reaction was stopped with cyclohexylacetylene.

To extend the synthetic utility of this cascade reaction, we made further efforts to the transformation of 1,2-dihydrobenzofuro[3,2-*b*]pyridines. Benzofuro[3,2-*b*]pyridine moieties have been found with various pharmaceutical and biological activities, such as antiallergic, anti-inflammatory, antimicrobial, and analgesic activity, cyclin-dependent kinase inhibitors, and topoisomerase inhibitors.<sup>10</sup> 1,2-Dihydrobenzofuro[3,2-*b*]pyridines were easily deprotected and aromatized to the corresponding benzofuro[3,2-*b*]-

Scheme 2. Substrate Scope<sup>a</sup>

<sup>a</sup>Conditions: **1** (0.20 mmol), **2** (0.60 mmol),  $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4$  (5 mol %), XantPhos (5 mol %),  $\text{Et}_3\text{N}$  (0.20 mmol), 1,4-dioxane (3.0 mL), 60 °C, 48 h.

pyridines under basic conditions through the E1cb mechanism (Scheme 3).

Scheme 3. Synthesis of Benzofuro[3,2-*b*]pyridines<sup>a</sup>

<sup>a</sup>Conditions: **3** (0.15 mmol), NaOH (0.75 mmol), EtOH (2.0 mL), reflux, 0.5 h.


A series of 1,2-dihydrobenzofuro[3,2-*b*]pyridines bearing both electron-donating and electron-withdrawing groups on the aromatic rings of substrates underwent deprotection and aromatization successfully, generating the desired benzofuro[3,2-*b*]pyridine products **4a–k** in excellent yields. It is worth noting that the benzofuro[3,2-*b*]pyridine bearing thienyl functionality **4l** could also be obtained in 96% yield. This method provides a practical and alternative route to a series of benzofuro[3,2-*b*]pyridines.

Encouraged by the results above, we decided to apply this new methodology to the one-pot synthesis of benzofuro[3,2-*b*]pyridines. As shown in Scheme 4, the corresponding benzofuro[3,2-*b*]pyridines **4** could be prepared from azadienes **1** and terminal alkynes **2** in 86–91% yields via the copper-catalyzed cascade reaction followed by basic deprotection and aromatization.

To evaluate the synthetic potential of this cascade reaction, a gram scale experiment of azadiene **1a** and phenylacetylene **2a** was conducted in the presence of the  $\text{Cu}(\text{CH}_3\text{CN})_4\text{BF}_4/\text{XantPhos}$  catalyst (5 mol %). Gratifyingly, the transformation proceeded smoothly to afford 1,2-dihydropyridine derivative **3aa** in 89% yield without noticeable loss of yield (Scheme 5).


To further demonstrate the synthetic utility, three bioactive molecules with potent topoisomerase (topo) inhibition were

### Scheme 4. One-Pot Synthesis of Benzofuro[3,2-*b*]pyridines<sup>a</sup>



<sup>a</sup>Conditions: **1** (0.20 mmol), **2** (0.60 mmol), Cu(CH<sub>3</sub>CN)<sub>4</sub>BF<sub>4</sub> (5 mol %), XantPhos (5 mol %), Et<sub>3</sub>N (0.20 mmol), 1,4-dioxane (3.0 mL), 60 °C, 48 h. Then, NaOH (1.0 mmol), 80 °C, 2 h.

### Scheme 5. Gram Scale Experiment and Synthesis of Three Bioactive Molecules



synthesized in high yields (Scheme 5). 4-Chlorophenyl-substituted benzofuro[3,2-*b*]pyridine **5** exhibits potent topo II inhibition and antiproliferative activity,<sup>10e</sup> which could be conveniently obtained in 90% yield using the one-pot synthesis. Additionally, the compound **6** which showed endogenous topo I and II inhibitory activities<sup>10d</sup> could be achieved in 89% yield with the same method. 3-(4-Phenylbenzofuro[3,2-*b*]pyridin-2-yl)phenol **7** has been determined to be a nonintercalative topo I and II dual catalytic inhibitors,<sup>10d</sup> and could also be synthesized with 87% yield through deprotection of methyl with tribromoboron.

## CONCLUSIONS

In conclusion, an efficient copper-catalyzed alkylation/cyclization/isomerization cascade has been developed, giving a variety of 1,2-dihydrobenzofuro[3,2-*b*]pyridines with high yields. The obtained 1,2-dihydrobenzofuro[3,2-*b*]pyridines can be conveniently transformed into the corresponding aromatic benzofuro[3,2-*b*]pyridines in high yields under the basic conditions. Additionally, the one-pot synthesis of benzofuro[3,2-*b*]pyridines can also be realized from azadienes and terminal alkynes via copper-catalyzed cascade reactions and basic deprotection and aromatization. The synthetic utility of

this methodology was demonstrated by the synthesis of three bioactive molecules with potent topoisomerase inhibition in high yields. This protocol not only provides a facile approach to 1,2-dihydrobenzofuro[3,2-*b*]pyridines but also affords new access to aromatic benzofuro[3,2-*b*]pyridines.

## EXPERIMENTAL SECTION

All reactions were carried out under an atmosphere of nitrogen using the standard Schlenk techniques unless otherwise noted. Commercially available reagents were used without further purification. Solvents were treated prior to use according to the standard methods. <sup>1</sup>H NMR, <sup>13</sup>C NMR spectra were recorded at 400 and 100 MHz with a Bruker spectrometer. <sup>19</sup>F NMR spectra were recorded at 376 MHz with a Bruker spectrometer. Chemical shifts are reported in ppm using tetramethylsilane as an internal standard when using CDCl<sub>3</sub> as a solvent for <sup>1</sup>H NMR spectra. The following abbreviations were used to symbolize the multiplicities: s = singlet, d = doublet, t = triplet, m = multiplet, and brs = broad singlet. Flash column chromatography was performed on silica gel (200–300 mesh). All reactions were monitored by thin-layer chromatography (TLC) analysis. High-resolution mass spectrometry [HRMS (ESI-TOF) *m/z*] was measured on an electrospray ionization (ESI) apparatus using time-of-flight (TOF) mass spectrometry. The heat source in reaction procedures was an oil bath.

**Procedures for Synthesis of Azadienes.** Azadienes **1** could be synthesized from enones and sulfonamides according to the known literature procedures.<sup>9,11,12</sup> Among them, azadienes **1a–d**,<sup>9a</sup> **1e**,<sup>9i</sup> **1f–j**,<sup>9a</sup> **1k**,<sup>9r</sup> **1l**,<sup>9j</sup> **1m**,<sup>9c</sup> and **1n**<sup>9i</sup> are the known compound. Starting materials benzofuran-3(2*H*)-ones<sup>12</sup> and intermediate enones<sup>9,11</sup> are the known compounds.

Under nitrogen, aluminum oxide (65 g, activated, basic) was added to a solution of ketones (20 mmol) and aldehydes (40 mmol) in dichloromethane (80 mL). The mixture was stirred at room temperature under nitrogen and exclusion of light. The reaction progress was monitored by TLC. The suspension was filtered off, the residue was washed with dichloromethane, and the filtrate was combined with the filtrate. The solvent was evaporated in vacuo. The residue was purified by flash chromatography and recrystallized from ethyl acetate/hexanes to give the intermediate enones for the next step.

To a solution of the above enones (5 mmol) and sulfonamides (5 mmol) in toluene (50 mL), triethylamine (1.39 mL, 10 mmol) and titanium tetrachloride (0.55 mL, 5 mmol) were successively added at 0 °C in an ice bath. The reaction mixture was heated in an oil bath for reflux overnight. The solution was cooled, quenched with water, and extracted with dichloromethane. The combined organic phase was dried over anhydrous sodium sulfate and concentrated. The residue was purified by silica gel flash chromatography using ethyl acetate/hexanes as the eluent, and further recrystallized from ethyl acetate/hexanes to give the pure azadienes **1**.

**4-Methyl-N-((Z)-2-((Z)-4-(trifluoromethyl)benzylidene)benzofuran-3(2*H*)-ylidene)benzenesulfonamide (1o).** 0.401 g, 18% yield, yellow solid, m.p. = 145–146 °C, new compound, *R*<sub>f</sub> = 0.50 (hexanes/ethyl acetate = 40/1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.78 (d, *J* = 7.6 Hz, 1H), 8.19–7.88 (m, 4H), 7.79–7.59 (m, 3H), 7.53–7.28 (m, 4H), 7.04 (s, 1H), 2.48 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 164.9, 164.8, 150.9, 143.8, 138.7, 138.1, 135.7, 131.6, 131.5, 131.1 (q, *J*<sub>C–F</sub> = 32.0 Hz), 129.6, 127.2, 125.8 (q, *J*<sub>C–F</sub> = 4.0 Hz), 124.2, 123.9 (q, *J*<sub>C–F</sub> = 271.0 Hz), 118.0, 112.8, 112.5, 21.7; <sup>19</sup>F{<sup>1</sup>H} NMR (376 MHz, CDCl<sub>3</sub>) δ –62.8. HRMS (ESI-TOF) *m/z* calcd for C<sub>23</sub>H<sub>17</sub>F<sub>3</sub>NO<sub>3</sub>S [M + H]<sup>+</sup> 444.0876, found 444.0879.

**General Procedure for the Synthesis of Dihydrobenzofuro[3,2-*b*]pyridines.** Under nitrogen, the solution of Cu(MeCN)<sub>4</sub>BF<sub>4</sub> (3.1 mg, 0.01 mmol) and ligand XantPhos (5.8 mg, 0.01 mmol) in 1,4-dioxane (0.5 mL) was stirred at room temperature for 1.5 h, and azadienes **1** (0.20 mmol), 1,4-dioxane (2.5 mL), triethylamine (20.2 mg, 0.2 mmol), and terminal alkynes **2** (0.6 mmol) were added in sequence. The reaction mixture was stirred at 60 °C in an oil bath for 2 days, which was monitored by thin-layer chromatography. The

solvent was evaporated under the reduced pressure and the crude product was directly purified by silica gel column chromatography (eluent: hexanes/ethyl acetate = 50:1–30:1) to give the desired products 3.

**2,4-Diphenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3aa).** 91 mg, 95% yield, pale yellow solid, m.p. = 178–179 °C, new compound,  $R_f$  = 0.30 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.11–7.89 (m, 1H), 7.54–7.41 (m, 4H), 7.41–7.33 (m, 4H), 7.34–7.27 (m, 3H), 7.26–7.18 (m, 4H), 7.07 (d,  $J$  = 7.9 Hz, 2H), 6.12 (d,  $J$  = 5.7 Hz, 1H), 5.88–5.61 (m, 1H), 2.25 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  154.0, 147.4, 144.2, 138.1, 134.6, 134.1, 131.1, 129.3, 128.7, 128.7, 128.5, 128.3, 127.6, 127.6, 127.4, 125.3, 124.6, 123.8, 121.9, 121.7, 117.5, 111.7, 59.4, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{30}\text{H}_{24}\text{NO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  478.1471, found: 478.1473.

**2-Phenyl-4-(*o*-tolyl)-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ba).** 91 mg, 93% yield, pale yellow solid, m.p. = 174–175 °C, new compound,  $R_f$  = 0.30 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.18–8.01 (m, 1H), 7.62–7.49 (m, 4H), 7.37–7.26 (m, 6H), 7.26–7.23 (m, 1H), 7.22–7.11 (m, 4H), 6.86 (d,  $J$  = 7.4 Hz, 1H), 6.20 (d,  $J$  = 5.9 Hz, 1H), 5.72 (d,  $J$  = 5.9 Hz, 1H), 2.38 (s, 3H), 1.77 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  154.0, 147.4, 144.2, 138.8, 136.6, 135.6, 134.3, 131.6, 130.3, 129.7, 129.6, 128.9, 128.8, 128.4, 127.8, 127.3, 126.0, 125.1, 124.6, 123.7, 123.1, 122.1, 116.1, 111.7, 59.6, 21.6, 19.7. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{31}\text{H}_{26}\text{NO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  492.1628, found: 492.1635.

**2-Phenyl-4-(*m*-tolyl)-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ca).** 92 mg, 94% yield, pale yellow solid, m.p. = 163–164 °C, new compound,  $R_f$  = 0.30 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.15–7.86 (m, 1H), 7.50–7.43 (m, 4H), 7.42–7.36 (m, 1H), 7.33–7.26 (m, 4H), 7.26–7.20 (m, 2H), 7.18 (d,  $J$  = 7.7 Hz, 1H), 7.08 (d,  $J$  = 8.0 Hz, 2H), 7.04–6.97 (m, 2H), 6.11 (d,  $J$  = 6.1 Hz, 1H), 5.73 (d,  $J$  = 6.0 Hz, 1H), 2.38 (s, 3H), 2.27 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  154.0, 147.5, 144.2, 138.2, 134.6, 134.2, 131.3, 129.5, 129.3, 128.7, 128.4, 128.3, 127.7, 127.4, 125.2, 124.8, 124.7, 123.8, 121.9, 121.7, 117.4, 111.7, 59.4, 21.6, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{31}\text{H}_{26}\text{NO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  492.1628, found: 492.1618.

**2-Phenyl-4-(*p*-tolyl)-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3da).** 94 mg, 96% yield, white solid, m.p. = 175–176 °C, new compound,  $R_f$  = 0.30 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.01–7.97 (m, 1H), 7.49–7.42 (m, 4H), 7.40–7.35 (m, 1H), 7.33–7.26 (m, 3H), 7.25–7.20 (m, 2H), 7.19–7.14 (m, 2H), 7.14–7.08 (m, 2H), 7.07 (d,  $J$  = 8.0 Hz, 2H), 6.10 (d,  $J$  = 6.1 Hz, 1H), 5.72 (d,  $J$  = 6.1 Hz, 1H), 2.38 (s, 3H), 2.26 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  153.9, 147.5, 144.2, 138.6, 138.2, 134.6, 131.2, 131.0, 129.2, 129.2, 128.6, 128.3, 127.6, 127.5, 127.4, 125.2, 124.7, 123.8, 121.8, 121.1, 117.3, 111.6, 59.4, 21.5, 21.4. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{31}\text{H}_{26}\text{NO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  492.1628, found: 492.1615.

**4-(4-Isopropylphenyl)-2-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ea).** 103 mg, 99% yield, pale yellow solid, m.p. = 169–170 °C, new compound,  $R_f$  = 0.40 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.05–7.97 (m, 1H), 7.51–7.43 (m, 4H), 7.42–7.38 (m, 1H), 7.33–7.27 (m, 3H), 7.26–7.22 (m, 4H), 7.21–7.16 (m, 2H), 7.08 (d,  $J$  = 8.0 Hz, 2H), 6.11 (d,  $J$  = 6.1 Hz, 1H), 5.74 (d,  $J$  = 6.1 Hz, 1H), 2.95 (hept,  $J$  = 6.9 Hz, 1H), 2.25 (s, 3H), 1.30 (s, 3H), 1.28 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  154.0, 149.6, 147.6, 144.2, 138.3, 134.6, 131.6, 130.9, 129.3, 128.6, 128.3, 127.6, 127.6, 127.4, 126.6, 125.2, 124.7, 123.8, 121.9, 121.2, 117.4, 111.7, 59.4, 34.1, 24.1, 24.0, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{33}\text{H}_{30}\text{NO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  520.1941, found: 520.1931.

**4-(4-Methoxyphenyl)-2-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3fa).** 94 mg, 93% yield, pale yellow solid, m.p. = 169–170 °C, new compound,  $R_f$  = 0.50 (hexanes/ethyl acetate = 10:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.08–7.91 (m, 1H), 7.48–7.42 (m, 4H), 7.41–7.36 (m, 1H), 7.33–7.26 (m, 3H), 7.25–7.16 (m, 4H), 7.07 (d,  $J$  = 8.0 Hz, 2H), 6.92–6.86 (m, 2H), 6.10 (d,  $J$  = 6.1 Hz, 1H), 5.69 (d,  $J$  = 6.1 Hz, 1H), 3.84 (s, 3H), 2.26 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  160.0, 153.9, 147.6, 144.2,

138.3, 134.6, 130.5, 129.2, 128.9, 128.6, 128.7, 127.6, 127.4, 126.5, 125.2, 124.7, 123.8, 121.8, 120.4, 117.4, 113.9, 111.6, 59.4, 55.5, 21.6. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{31}\text{H}_{26}\text{NO}_4\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  508.1577, found: 508.1572.

**4-(4-Chlorophenyl)-2-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ga).** 98 mg, 96% yield, pale yellow solid, m.p. = 177–178 °C, new compound,  $R_f$  = 0.55 (hexanes/ethyl acetate = 10:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.30–7.70 (m, 1H), 7.46 (d,  $J$  = 8.2 Hz, 4H), 7.43–7.38 (m, 1H), 7.38–7.29 (m, 5H), 7.28–7.23 (m, 2H), 7.22–7.15 (m, 2H), 7.09 (d,  $J$  = 8.0 Hz, 2H), 6.14 (d,  $J$  = 6.1 Hz, 1H), 5.77 (d,  $J$  = 6.1 Hz, 1H), 2.29 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  154.0, 146.9, 144.3, 137.9, 134.7, 134.6, 132.5, 130.0, 129.3, 128.9, 128.7, 128.7, 128.4, 127.7, 127.3, 125.5, 124.5, 124.0, 122.0, 117.8, 111.7, 59.4, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{30}\text{H}_{23}\text{ClNO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  512.1082, found: 512.1100.

**4-(3-Chlorophenyl)-2-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ha).** 99 mg, 97% yield, pale yellow solid, m.p. = 70–72 °C, new compound,  $R_f$  = 0.45 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.08–7.98 (m, 1H), 7.51–7.40 (m, 5H), 7.39–7.30 (m, 5H), 7.29–7.23 (m, 2H), 7.22–7.16 (m, 1H), 7.16–7.07 (m, 3H), 6.14 (d,  $J$  = 6.1 Hz, 1H), 5.77 (d,  $J$  = 6.1 Hz, 1H), 2.31 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  154.0, 146.8, 144.5, 137.8, 135.9, 134.5, 134.4, 130.0, 129.8, 129.3, 128.7, 128.4, 127.7, 127.3, 125.8, 125.5, 124.5, 124.0, 122.6, 122.0, 117.8, 111.8, 59.4, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{30}\text{H}_{23}\text{ClNO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  512.1082, found: 512.1075.

**4-(3-Bromophenyl)-2-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ia).** 109 mg, 99% yield, pale yellow solid, m.p. = 75–76 °C, new compound,  $R_f$  = 0.45 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.13–7.91 (m, 1H), 7.53–7.46 (m, 1H), 7.46–7.38 (m, 5H), 7.34–7.26 (m, 4H), 7.25–7.18 (m, 4H), 7.09 (d,  $J$  = 8.1 Hz, 2H), 6.11 (d,  $J$  = 6.1 Hz, 1H), 5.73 (d,  $J$  = 6.1 Hz, 1H), 2.30 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  154.0, 146.8, 144.5, 137.8, 136.2, 134.5, 131.6, 130.6, 130.1, 129.9, 129.3, 128.7, 128.5, 127.7, 127.3, 126.3, 125.5, 124.5, 124.0, 122.7, 122.5, 122.0, 117.8, 111.8, 59.4, 21.6. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{30}\text{H}_{23}\text{BrNO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  556.0577, found: 556.0568.

**4-(Naphthalen-1-yl)-2-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ja).** 103 mg, 98% yield, pale yellow solid, m.p. = 185–187 °C, new compound,  $R_f$  = 0.35 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  8.06 (d,  $J$  = 7.9 Hz, 1H), 7.81 (t,  $J$  = 8.1 Hz, 2H), 7.56 (t,  $J$  = 7.2 Hz, 4H), 7.40 (t,  $J$  = 7.5 Hz, 2H), 7.33–7.21 (m, 4H), 7.20–7.03 (m, 6H), 6.71 (brs, 1H), 6.25 (d,  $J$  = 5.8 Hz, 1H), 5.89 (d,  $J$  = 5.8 Hz, 1H), 2.27 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  154.1, 147.8, 144.3, 138.8, 135.6, 133.6, 132.6, 131.4, 130.7, 129.8, 129.4, 128.8, 128.4, 128.4, 127.9, 127.3, 126.1, 126.1, 125.5, 125.5, 125.2, 124.5, 124.2, 123.7, 122.1, 111.8, 59.6, 21.8. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{34}\text{H}_{26}\text{NO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  528.1628, found: 528.1638.

**8-Methyl-2,4-diphenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ka).** 94 mg, 96% yield, pale yellow solid, m.p. = 160–162 °C, new compound,  $R_f$  = 0.30 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.79 (s, 1H), 7.54–7.43 (m, 4H), 7.42–7.32 (m, 3H), 7.30–7.18 (m, 6H), 7.14–6.97 (m, 3H), 6.11 (d,  $J$  = 6.1 Hz, 1H), 5.73 (d,  $J$  = 6.1 Hz, 1H), 2.46 (s, 3H), 2.24 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  152.5, 147.6, 144.2, 138.2, 134.6, 134.2, 133.4, 131.2, 129.2, 128.6, 128.5, 128.3, 127.7, 127.6, 127.4, 126.7, 124.7, 121.5, 121.5, 117.2, 111.2, 59.4, 21.6, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $\text{C}_{31}\text{H}_{26}\text{NO}_3\text{S}$  [ $\text{M} + \text{H}$ ] $^+$  492.1628, found: 492.1623.

**7-Methyl-2,4-diphenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3la).** 96 mg, 98% yield, pale yellow solid, m.p. = 139–141 °C, new compound,  $R_f$  = 0.30 (hexanes/ethyl acetate = 30:1).  $^1\text{H}$  NMR (400 MHz,  $\text{CDCl}_3$ )  $\delta$  7.89 (d,  $J$  = 8.1 Hz, 1H), 7.54–7.43 (m, 4H), 7.40–7.33 (m, 3H), 7.30–7.20 (m, 6H), 7.16–7.11 (m, 1H), 7.07 (d,  $J$  = 8.0 Hz, 2H), 6.11 (d,  $J$  = 6.1 Hz, 1H), 5.72 (d,  $J$  = 6.1 Hz, 1H), 2.46 (s, 3H), 2.25 (s, 3H);  $^{13}\text{C}\{^1\text{H}\}$  NMR (100 MHz,  $\text{CDCl}_3$ )  $\delta$  154.4, 146.8, 144.1, 138.3, 135.8, 134.6, 134.3, 131.1, 129.2, 128.6, 128.5, 128.3, 127.6, 127.6, 127.4, 125.3, 122.2, 121.3, 120.9, 117.5,

111.9, 59.4, 21.9, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{31}H_{26}NO_3S$   $[M + H]^+$  492.1628, found: 492.1603.

**1-(Methylsulfonyl)-2,4-diphenyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ma).** 71 mg, 89% yield, pale yellow solid, m.p. = 154–155 °C, new compound,  $R_f$  = 0.15 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.03–7.88 (m, 1H), 7.87–7.74 (m, 2H), 7.60–7.42 (m, 6H), 7.36–7.22 (m, 5H), 6.34 (d,  $J$  = 6.1 Hz, 1H), 6.12 (d,  $J$  = 6.1 Hz, 1H), 2.94 (s, 3H);  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  154.2, 146.4, 138.1, 133.9, 131.8, 129.3, 129.0, 128.7, 128.5, 127.7, 127.2, 125.6, 124.2, 123.9, 121.8, 121.2, 117.9, 111.8, 59.2, 37.1. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{24}H_{20}NO_3S$   $[M + H]^+$  402.1158, found: 402.1148.

**7-Methyl-1-((4-nitrophenyl)sulfonyl)-2,4-diphenyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3na).** 62 mg, 61% yield, pale yellow solid, m.p. = 192–193 °C, new compound,  $R_f$  = 0.20 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.11 (d,  $J$  = 8.7 Hz, 2H), 8.04–7.89 (m, 1H), 7.77 (d,  $J$  = 8.7 Hz, 2H), 7.58–7.40 (m, 3H), 7.40–7.27 (m, 7H), 7.25–7.19 (m, 2H), 6.16 (d,  $J$  = 6.0 Hz, 1H), 5.84 (d,  $J$  = 6.0 Hz, 1H);  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  154.1, 150.3, 147.5, 143.0, 137.2, 133.3, 131.5, 129.2, 128.9, 128.8, 128.7, 127.3, 127.2, 125.8, 124.2, 124.0, 123.8, 121.6, 121.3, 116.9, 112.0, 59.8. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{32}H_{17}N_2O_5$   $[M + H]^+$  509.1132, found: 509.1150.

**2-Phenyl-1-tosyl-4-(4-(trifluoromethyl)phenyl)-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3oa).** 62 mg, 57% yield, white solid, m.p. = 158–159 °C, new compound,  $R_f$  = 0.35 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.13–7.96 (m, 1H), 7.66 (d,  $J$  = 8.3 Hz, 2H), 7.49 (d,  $J$  = 8.2 Hz, 4H), 7.46–7.41 (m, 1H), 7.41–7.29 (m, 6H), 7.29–7.24 (m, 1H), 7.11 (d,  $J$  = 8.0 Hz, 2H), 6.19 (d,  $J$  = 6.1 Hz, 1H), 5.86 (d,  $J$  = 6.1 Hz, 1H), 2.28 (s, 3H).  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  154.0, 146.6, 144.3, 137.7, 137.6, 134.5, 130.7 (q,  $J_{C-F}$  = 32.0 Hz), 129.9, 129.3, 128.8, 128.5, 127.9, 127.7, 127.3, 125.6, 125.5 (q,  $J_{C-F}$  = 4.0 Hz), 124.5, 124.1 (q,  $J_{C-F}$  = 271.0 Hz), 124.0, 123.1, 122.0, 118.0, 111.7, 59.4, 21.5.  $^{19}F\{^1H\}$  NMR (376 MHz,  $CDCl_3$ )  $\delta$  –62.6. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{31}H_{23}F_3NO_3S$   $[M + H]^+$  546.1345, found: 546.1336.

**4-Phenyl-2-(*p*-tolyl)-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ab).** 90 mg, 92% yield, pale yellow solid, m.p. = 199–201 °C, new compound,  $R_f$  = 0.30 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.11–7.95 (m, 1H), 7.50–7.44 (m, 2H), 7.43–7.33 (m, 6H), 7.33–7.27 (m, 2H), 7.26–7.22 (m, 2H), 7.17–6.98 (m, 4H), 6.11 (d,  $J$  = 6.0 Hz, 1H), 5.76 (d,  $J$  = 6.0 Hz, 1H), 2.28 (s, 3H), 2.26 (s, 3H);  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  154.0, 147.4, 144.2, 138.2, 135.0, 134.6, 134.2, 131.0, 129.4, 129.3, 128.6, 128.5, 127.7, 127.6, 127.4, 125.2, 124.7, 123.8, 122.0, 121.9, 117.4, 111.7, 59.3, 21.5, 21.2. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{31}H_{26}NO_3S$   $[M + H]^+$  492.1628, found: 492.1620.

**4-Phenyl-2-(*m*-tolyl)-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ac).** 88 mg, 90% yield, white solid, m.p. = 151–152 °C, new compound,  $R_f$  = 0.30 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.15–7.95 (m, 1H), 7.52 (d,  $J$  = 8.2 Hz, 2H), 7.48–7.40 (m, 4H), 7.40–7.31 (m, 5H), 7.31–7.27 (m, 1H), 7.20 (t,  $J$  = 7.6 Hz, 1H), 7.14–7.06 (m, 3H), 6.17 (d,  $J$  = 6.1 Hz, 1H), 5.82 (d,  $J$  = 6.1 Hz, 1H), 2.35 (s, 3H), 2.29 (s, 3H);  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  153.9, 147.4, 144.2, 138.3, 138.0, 134.5, 134.1, 130.9, 129.2, 129.1, 128.6, 128.5, 128.4, 128.1, 127.6, 127.6, 125.2, 124.7, 124.4, 123.7, 121.9, 121.8, 117.4, 111.6, 59.4, 21.5, 21.4. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{31}H_{26}NO_3S$   $[M + H]^+$  492.1628, found: 492.1627.

**2-(4-Methoxyphenyl)-4-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ad).** 93 mg, 92% yield, white solid, m.p. = 201–202 °C, new compound,  $R_f$  = 0.20 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.10–7.84 (m, 1H), 7.45 (d,  $J$  = 8.3 Hz, 2H), 7.42–7.33 (m, 6H), 7.33–7.27 (m, 2H), 7.25–7.19 (m, 2H), 7.07 (d,  $J$  = 8.0 Hz, 2H), 6.83–6.75 (m, 2H), 6.07 (d,  $J$  = 6.0 Hz, 1H), 5.71 (d,  $J$  = 6.0 Hz, 1H), 3.73 (s, 3H), 2.24 (s, 3H);  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  159.7, 154.0, 147.4, 144.1, 134.6, 134.2, 130.9, 129.8, 129.2, 128.8, 128.6, 128.5, 127.6, 125.2, 124.7, 123.8, 122.0, 121.9, 117.3, 114.1, 111.6, 59.1, 55.3, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{31}H_{26}NO_4S$   $[M + H]^+$  508.1577, found: 508.1575.

**2-(4-Fluorophenyl)-4-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ae).** 94 mg, 95% yield, white solid, m.p. = 193–194 °C, new compound,  $R_f$  = 0.35 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.04–7.89 (m, 1H), 7.49–7.33 (m, 8H), 7.30 (m, 2H), 7.21 (m, 2H), 7.06 (d,  $J$  = 8.0 Hz, 2H), 6.93 (t,  $J$  = 8.7 Hz, 2H), 6.06 (d,  $J$  = 6.0 Hz, 1H), 5.70 (d,  $J$  = 6.0 Hz, 1H), 2.23 (s, 3H);  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  162.8 (d,  $J_{C-F}$  = 247.1 Hz), 154.0, 147.3, 144.3, 134.5, 134.0, 133.8 (d,  $J_{C-F}$  = 2.9 Hz), 131.3, 129.3, 129.2 (d,  $J_{C-F}$  = 8.4 Hz), 128.8, 128.5, 127.6, 127.6, 125.4, 124.5, 123.9, 121.9, 121.3, 117.4, 115.6 (d,  $J_{C-F}$  = 21.7 Hz), 111.7, 58.8, 21.5;  $^{19}F\{^1H\}$  NMR (376 MHz,  $CDCl_3$ )  $\delta$  –113.8. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{30}H_{23}FNO_3S$   $[M + H]^+$  496.1377, found: 496.1370.

**2-(4-Bromophenyl)-4-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3af).** 101 mg, 91% yield, yellow solid, m.p. = 214–216 °C, new compound,  $R_f$  = 0.35 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.09–7.89 (m, 1H), 7.47–7.41 (m, 2H), 7.41–7.27 (m, 10H), 7.25–7.18 (m, 2H), 7.07 (d,  $J$  = 8.0 Hz, 2H), 6.05 (d,  $J$  = 6.1 Hz, 1H), 5.71 (d,  $J$  = 6.1 Hz, 1H), 2.24 (s, 3H);  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  154.0, 147.2, 144.4, 137.3, 134.4, 133.9, 131.8, 131.5, 129.3, 129.1, 128.8, 128.5, 127.6, 127.6, 125.5, 124.4, 124.0, 122.4, 121.8, 120.8, 117.5, 111.8, 58.8, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{30}H_{23}BrNO_3S$   $[M + H]^+$  556.0577, found: 556.0574.

**4-Phenyl-1-tosyl-2-(4-(trifluoromethyl)phenyl)-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ag).** 69 mg, 63% yield, white solid, m.p. = 170–171 °C,  $R_f$  = 0.35 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.07–7.92 (m, 1H), 7.71–7.48 (m, 4H), 7.48–7.43 (m, 2H), 7.42–7.35 (m, 4H), 7.35–7.28 (m, 2H), 7.25–7.19 (m, 2H), 7.08 (d,  $J$  = 8.0 Hz, 2H), 6.15 (d,  $J$  = 6.1 Hz, 1H), 5.76 (d,  $J$  = 6.1 Hz, 1H), 2.25 (s, 3H).  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  154.0, 147.2, 144.5, 142.4, 134.3, 133.8, 131.7, 130.5 (q,  $J_{C-F}$  = 32.0 Hz), 129.4, 128.9, 128.6, 127.6, 127.6, 126.0, 125.6 (q,  $J_{C-F}$  = 4.0 Hz), 125.6, 124.3, 124.1 (q,  $J_{C-F}$  = 271.0 Hz), 124.0, 121.8, 120.5, 117.6, 111.8, 58.8, 21.5.  $^{19}F\{^1H\}$  NMR (376 MHz,  $CDCl_3$ )  $\delta$  –62.6. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{31}H_{23}F_3NO_3S$   $[M + H]^+$  546.1345, found: 546.1345.

**4-Phenyl-2-(thiophen-3-yl)-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ah).** 84 mg, 87% yield, white solid, m.p. = 90–91 °C, new compound,  $R_f$  = 0.20 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.07–7.95 (m, 1H), 7.45 (d,  $J$  = 8.3 Hz, 2H), 7.43–7.34 (m, 4H), 7.34–7.28 (m, 2H), 7.25–7.18 (m, 4H), 7.17–7.12 (m, 1H), 7.07 (d,  $J$  = 8.1 Hz, 2H), 6.15 (d,  $J$  = 5.9 Hz, 1H), 5.76 (d,  $J$  = 5.9 Hz, 1H), 2.25 (s, 3H);  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  154.0, 147.2, 144.2, 139.2, 134.6, 134.1, 130.7, 129.3, 128.7, 128.5, 127.6, 126.8, 126.4, 125.3, 124.6, 123.9, 123.3, 121.8, 121.8, 117.5, 111.7, 56.4, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{28}H_{22}NO_3S_2$   $[M + H]^+$  484.1036, found: 484.1041.

**2-(tert-Butyl)-4-phenyl-1-tosyl-1,2-dihydrobenzofuro[3,2-*b*]pyridine (3ai).** 10 mg, 11% yield, yellow oil,  $R_f$  = 0.45 (hexanes/ethyl acetate = 30:1).  $^1H$  NMR (400 MHz,  $CDCl_3$ )  $\delta$  8.11–8.02 (m, 1H), 7.43–7.35 (m, 4H), 7.34–7.28 (m, 4H), 7.17–7.09 (m, 2H), 7.02 (d,  $J$  = 8.1 Hz, 2H), 5.52 (d,  $J$  = 5.9 Hz, 1H), 4.63 (d,  $J$  = 5.9 Hz, 1H), 2.22 (s, 3H), 0.93 (s, 9H);  $^{13}C\{^1H\}$  NMR (100 MHz,  $CDCl_3$ )  $\delta$  153.9, 147.8, 143.9, 134.5, 134.2, 130.9, 129.0, 128.5, 128.4, 127.7, 127.5, 125.1, 124.7, 123.9, 122.6, 121.7, 119.0, 111.7, 66.2, 37.6, 25.9, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for  $C_{28}H_{28}NO_3S$   $[M + H]^+$  458.1784, found: 458.1789.

**General Procedure for the Synthesis of Benzofuro[3,2-*b*]pyridines.** The aromatization of 1,2-dihydrobenzofuro[3,2-*b*]pyridines **3** were conveniently conducted in ethanol through deprotection of the tosyl group in the presence of sodium hydroxide according to the known literature procedure.<sup>13</sup>

To the solution of the cyclization products **3** (0.15 mmol) in anhydrous ethanol (2.0 mL), powder sodium hydroxide (30 mg, 0.75 mmol) was added, the reaction mixture was refluxed in an oil bath for 30 min. The solvent was evaporated under the reduced pressure, the crude product was purified by silica gel column chromatography using hexanes/ethyl acetate as the eluent to give the desirable aromatization products **4**.

**2,4-Diphenylbenzofuro[3,2-*b*]pyridine (4a).** 43 mg, 89% yield, white solid, the known compound,<sup>14</sup>  $R_f = 0.85$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.37 (d,  $J = 7.7$  Hz, 1H), 8.17 (d,  $J = 8.1$  Hz, 2H), 8.11–8.03 (m, 2H), 7.96 (s, 1H), 7.67–7.50 (m, 7H), 7.50–7.43 (m, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.0, 154.5, 146.6, 145.1, 139.9, 134.3, 132.7, 129.5, 129.2, 129.1, 128.9, 128.9, 128.7, 127.4, 123.8, 123.7, 121.7, 117.8, 112.4.

**2-Phenyl-4-(*o*-tolyl)benzofuro[3,2-*b*]pyridine (4b).** 45 mg, 90% yield, white solid, m.p. = 54–56 °C, new compound,  $R_f = 0.85$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.37 (d,  $J = 7.7$  Hz, 1H), 8.15 (d,  $J = 7.4$  Hz, 2H), 7.75 (s, 1H), 7.63–7.50 (m, 4H), 7.51–7.32 (m, 6H), 2.34 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.0, 154.0, 147.0, 144.4, 139.8, 136.7, 134.5, 133.9, 130.7, 130.0, 129.3, 129.2, 129.0, 128.8, 127.4, 126.2, 124.0, 123.7, 121.7, 120.2, 112.4, 20.4. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>24</sub>H<sub>18</sub>NO [M + H]<sup>+</sup> 336.1383, found: 336.1386.

**2-Phenyl-4-(*m*-tolyl)benzofuro[3,2-*b*]pyridine (4c).** 48 mg, 95% yield, white solid, m.p. = 139–140 °C, new compound,  $R_f = 0.85$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.42–8.33 (m, 1H), 8.24–7.10 (m, 2H), 7.95 (s, 1H), 7.90–7.78 (m, 2H), 7.66 (d,  $J = 8.3$  Hz, 1H), 7.62–7.52 (m, 3H), 7.53–7.44 (m, 3H), 7.35 (d,  $J = 7.6$  Hz, 1H), 2.53 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.0, 154.4, 146.7, 145.0, 140.0, 138.8, 134.2, 132.9, 130.3, 129.4, 129.2, 129.0, 128.9, 128.7, 127.4, 126.1, 123.8, 123.6, 121.7, 117.9, 112.4, 21.8. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>24</sub>H<sub>18</sub>NO [M + H]<sup>+</sup> 336.1383, found: 336.1382.

**2-Phenyl-4-(*p*-tolyl)benzofuro[3,2-*b*]pyridine (4d).** 46 mg, 91% yield, white solid, m.p. = 120–122 °C, new compound,  $R_f = 0.85$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.35 (d,  $J = 7.6$  Hz, 1H), 8.19–8.09 (m, 2H), 8.04–7.87 (m, 3H), 7.65 (d,  $J = 8.3$  Hz, 1H), 7.61–7.51 (m, 3H), 7.51–7.36 (m, 4H), 2.48 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.9, 154.4, 146.6, 144.9, 140.0, 139.6, 132.6, 131.3, 129.8, 129.1, 128.9, 128.7, 128.7, 127.4, 123.8, 123.6, 121.6, 117.5, 112.3, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>24</sub>H<sub>18</sub>NO [M + H]<sup>+</sup> 336.1383, found: 336.1383.

**4-(4-Methoxyphenyl)-2-phenylbenzofuro[3,2-*b*]pyridine (4e).** 47 mg, 89% yield, white solid, m.p. = 141–142 °C, new compound,  $R_f = 0.70$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.45–8.28 (m, 1H), 8.21–8.11 (m, 2H), 8.04 (d,  $J = 8.7$  Hz, 2H), 7.92 (s, 1H), 7.67–7.51 (m, 4H), 7.45 (t,  $J = 7.3$  Hz, 2H), 7.11 (d,  $J = 8.7$  Hz, 2H), 3.91 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.7, 157.9, 154.4, 146.5, 144.9, 140.1, 132.3, 130.2, 129.1, 128.9, 128.7, 127.4, 126.5, 123.9, 123.6, 121.7, 117.2, 114.6, 112.3, 55.5. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>24</sub>H<sub>18</sub>NO<sub>2</sub> [M + H]<sup>+</sup> 352.1332, found: 352.1330.

**4-(4-Chlorophenyl)-2-phenylbenzofuro[3,2-*b*]pyridine (4f).** 47 mg, 93% yield, white solid, m.p. = 164–166 °C, new compound,  $R_f = 0.80$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.46–8.25 (m, 1H), 8.19–8.09 (m, 2H), 8.03–7.95 (m, 2H), 7.89 (s, 1H), 7.66–7.51 (m, 6H), 7.50–7.43 (m, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.9, 154.5, 146.3, 145.2, 139.8, 135.6, 132.7, 131.3, 130.2, 129.4, 129.0, 128.8, 127.4, 123.8, 123.7, 121.8, 117.3, 112.3. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>23</sub>H<sub>15</sub>ClNO [M + H]<sup>+</sup> 356.0837, found: 356.0837.

**8-Methyl-2,4-diphenylbenzofuro[3,2-*b*]pyridine (4g).** 46 mg, 91% yield, white solid, m.p. = 153–154 °C, new compound,  $R_f = 0.85$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.24–8.12 (m, 3H), 8.10–8.01 (m, 2H), 7.94 (s, 1H), 7.63–7.49 (m, 6H), 7.49–7.43 (m, 1H), 7.40–7.34 (m, 1H), 2.56 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  156.4, 154.2, 146.9, 145.1, 140.0, 134.4, 133.3, 132.5, 130.4, 129.4, 129.1, 128.9, 128.7, 127.4, 123.7, 121.5, 117.5, 111.8, 21.5. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>24</sub>H<sub>18</sub>NO [M + H]<sup>+</sup> 336.1383, found: 336.1371.

**7-Methyl-2,4-diphenylbenzofuro[3,2-*b*]pyridine (4h).** 47 mg, 93% yield, white solid, m.p. = 150–151 °C, new compound,  $R_f = 0.85$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.22 (d,  $J = 7.9$  Hz, 1H), 8.19–8.12 (m, 2H), 8.10–8.02 (m, 2H), 7.92 (s, 1H), 7.64–7.49 (m, 5H), 7.48–7.40 (m, 2H), 7.32–7.27 (m, 1H), 2.57 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.5, 154.3, 146.5, 145.3, 140.2, 140.1, 134.4, 132.4, 129.4, 129.1, 128.9, 128.7,

127.4, 125.1, 121.2, 121.2, 117.3, 112.6, 22.3. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>24</sub>H<sub>18</sub>NO [M + H]<sup>+</sup> 336.1383, found: 336.1376.

**4-Phenyl-2-(*p*-tolyl)benzofuro[3,2-*b*]pyridine (4i).** 46 mg, 92% yield, white solid, m.p. = 186–187 °C, new compound,  $R_f = 0.85$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.45–8.29 (m, 1H), 8.15–8.01 (m, 4H), 7.94 (d,  $J = 4.4$  Hz, 1H), 7.73–7.57 (m, 4H), 7.57–7.43 (m, 2H), 7.35 (d,  $J = 7.9$  Hz, 2H), 2.46 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.9, 154.5, 146.5, 144.9, 138.6, 137.1, 134.4, 132.6, 129.6, 129.4, 129.1, 129.1, 128.9, 127.2, 123.9, 123.6, 121.7, 117.4, 112.3, 21.4. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>24</sub>H<sub>18</sub>NO [M + H]<sup>+</sup> 336.1383, found: 336.1378.

**2-(4-Methoxyphenyl)-4-phenylbenzofuro[3,2-*b*]pyridine (4j).** 49 mg, 93% yield, white solid, m.p. = 162–164 °C, new compound,  $R_f = 0.70$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.34 (d,  $J = 7.6$  Hz, 1H), 8.17–8.09 (m, 2H), 8.09–8.00 (m, 2H), 7.90 (s, 1H), 7.70–7.49 (m, 5H), 7.49–7.42 (m, 1H), 7.06 (d,  $J = 8.8$  Hz, 2H), 3.90 (s, 3H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  160.4, 157.9, 154.2, 146.3, 144.9, 134.4, 132.7, 132.6, 129.4, 129.1, 128.9, 128.6, 123.9, 123.6, 121.7, 117.1, 114.3, 112.4, 55.5. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>24</sub>H<sub>18</sub>NO<sub>2</sub> [M + H]<sup>+</sup> 352.1332, found: 352.1325.

**2-(4-Bromophenyl)-4-phenylbenzofuro[3,2-*b*]pyridine (4k).** 54 mg, 90% yield, white solid, m.p. = 213–215 °C, new compound,  $R_f = 0.85$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.32 (d,  $J = 7.7$  Hz, 1H), 8.04 (d,  $J = 8.5$  Hz, 4H), 7.91 (s, 1H), 7.69–7.63 (m, 3H), 7.63–7.56 (m, 3H), 7.56–7.51 (m, 1H), 7.50–7.42 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  158.1, 153.1, 146.7, 145.2, 138.8, 134.1, 132.8, 132.0, 129.6, 129.4, 129.2, 128.9, 123.8, 123.7, 123.2, 121.7, 117.4, 112.4. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>23</sub>H<sub>15</sub>BrNO [M + H]<sup>+</sup> 400.0332, found: 400.0328.

**4-Phenyl-2-(thiophen-3-yl)benzofuro[3,2-*b*]pyridine (4l).** 47 mg, 96% yield, white solid, m.p. = 148–149 °C, new compound,  $R_f = 0.65$  (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>)  $\delta$  8.32 (d,  $J = 7.6$  Hz, 1H), 8.12–7.98 (m, 3H), 7.87 (s, 1H), 7.83 (m, 1H), 7.68–7.51 (m, 5H), 7.50–7.42 (m, 2H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>)  $\delta$  157.9, 150.5, 146.3, 144.9, 142.5, 134.2, 132.7, 129.5, 129.2, 129.1, 128.9, 126.8, 126.4, 123.7, 123.6, 123.2, 121.7, 117.4, 112.3. HRMS (ESI-TOF)  $m/z$  calcd for C<sub>21</sub>H<sub>14</sub>NOS [M + H]<sup>+</sup> 328.0791, found: 328.0791.

**One-Pot Synthesis of Benzofuro[3,2-*b*]pyridines.** Under nitrogen, the solution of Cu(MeCN)<sub>4</sub>BF<sub>4</sub> (3.1 mg, 0.01 mmol) and ligand XantPhos (5.8 mg, 0.01 mmol) in 1,4-dioxane (0.5 mL) was stirred at room temperature for 1.5 h, and azadienes **1** (0.20 mmol), 1,4-dioxane (2.5 mL), triethylamine (20.2 mg, 0.2 mmol), and terminal alkynes **2** (0.6 mmol) were added in sequence. The reaction mixture was stirred at 60 °C in an oil bath for 2 days, which was monitored by thin-layer chromatography, then powder sodium hydroxide (40 mg, 1.0 mmol) was added, the reaction was stirred at 80 °C in an oil bath for 2 h. The volatiles were evaporated under the reduced pressure, the residue was purified by silica gel column chromatography using hexanes/ethyl acetate as the eluent to give the desired products **4**.

**2,4-Diphenylbenzofuro[3,2-*b*]pyridine (4a):** 56 mg, 87% yield; **4-(4-chlorophenyl)-2-phenylbenzofuro[3,2-*b*]pyridine (4f):** 65 mg, 91% yield; **7-methyl-2,4-diphenylbenzofuro[3,2-*b*]pyridine (4h):** 61 mg, 86% yield.

**Experiment at Gram Scale.** Under nitrogen, the solution of Cu(MeCN)<sub>4</sub>BF<sub>4</sub> (39.3 mg, 0.125 mmol) and ligand XantPhos (72.3 mg, 0.125 mmol) in 1,4-dioxane (6.0 mL) was stirred at room temperature for 2 h, and azadiene **1a** (0.939 g, 2.5 mmol), 1,4-dioxane (31.5 mL), triethylamine (253 mg, 2.5 mmol), and terminal alkyne **2a** (0.768 g, 7.5 mmol) were added in sequence. The reaction mixture was stirred at 60 °C in an oil bath for 55 h, which was monitored by thin-layer chromatography. The volatiles were evaporated under the reduced pressure, the residue was purified by silica gel column chromatography using hexanes/ethyl acetate as the eluent to give the desired product **3aa**, 1.060 g, 89% yield.

**Synthesis of Three Bioactive Molecules. Synthesis of Bioactive Molecules 5 and 6.** Under nitrogen, the solution of Cu(MeCN)<sub>4</sub>BF<sub>4</sub> (7.8 mg, 0.025 mmol) and ligand XantPhos (14.5

mg, 0.025 mmol) in 1,4-dioxane (2.0 mL) was stirred at room temperature for 1.5 h, and azadienes **1a** (0.50 mmol), 1,4-dioxane (5.5 mL), triethylamine (50.6 mg, 0.50 mmol), and terminal alkynes (1.50 mmol) were added in sequence. The reaction mixture was stirred at 60 °C in an oil bath for 2 days, which was monitored by thin-layer chromatography, then powder sodium hydroxide (100 mg, 2.5 mmol) was added, the reaction was stirred at 80 °C in an oil bath for 2 h. The volatiles were evaporated under the reduced pressure, the residue was purified by silica gel column chromatography using hexanes/ethyl acetate = 80:1 as the eluent to give the bioactive compounds **5** and **6**.

**2-(4-Chlorophenyl)-4-phenylbenzofuro[3,2-b]pyridine (5)**. 160 mg, 90% yield, white solid, the known compound,<sup>10e</sup>  $R_f$  = 0.65 (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.35 (d,  $J$  = 7.7 Hz, 1H), 8.12 (d,  $J$  = 8.5 Hz, 2H), 8.06 (d,  $J$  = 7.4 Hz, 2H), 7.93 (s, 1H), 7.71–7.59 (m, 4H), 7.59–7.45 (m, 4H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 158.0, 153.1, 146.7, 145.2, 138.3, 134.9, 134.1, 132.8, 129.6, 129.4, 129.2, 129.1, 128.9, 128.6, 123.8, 123.6, 121.7, 117.4, 112.4.

**2-(3-Methoxyphenyl)-4-phenylbenzofuro[3,2-b]pyridine (6)**. 157 mg, 89% yield, colorless oil, the known compound,<sup>10d</sup>  $R_f$  = 0.60 (hexanes/ethyl acetate = 30:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.43–8.32 (m, 1H), 8.12–8.01 (m, 2H), 7.96 (s, 1H), 7.79–7.73 (m, 1H), 7.74–7.40 (m, 8H), 7.11–6.88 (m, 1H), 3.95 (s, 3H). <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 160.3, 158.0, 154.3, 146.7, 145.0, 141.4, 134.3, 132.7, 129.9, 129.5, 129.3, 129.2, 128.9, 123.8, 123.7, 121.8, 119.9, 118.0, 114.6, 112.9, 112.4, 55.6.

**Synthesis of Bioactive Molecule 7**. Under nitrogen, to the solution of **6** (0.157 g, 0.45 mmol) in dichloromethane (2.0 mL) was added BBr<sub>3</sub> (0.338 g, 1.35 mmol) in dichloromethane (3.0 mL) at –78 °C and stirred for 10 min, then the reaction mixture was moved to room temperature and stirred overnight.<sup>15</sup> The reaction was quenched with 20 mL water and extracted with dichloromethane, dried over anhydrous sodium sulfate, and concentrated. The crude products were purified by silica gel column chromatography using hexanes/ethyl acetate = 10:1 as the eluent to give the bioactive compounds **7**.

**3-(4-Phenylbenzofuro[3,2-b]pyridin-2-yl)phenol (7)**. 132 mg, 87% yield, shallow yellow solid, the known compound,<sup>10d</sup>  $R_f$  = 0.40 (hexanes/ethyl acetate = 5:1). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.46–8.25 (m, 1H), 8.14–7.97 (m, 2H), 7.92 (s, 1H), 7.89–7.82 (m, 1H), 7.66–7.49 (m, 6H), 7.43–7.32 (m, 2H), 7.05–6.80 (m, 1H); <sup>13</sup>C{<sup>1</sup>H} NMR (100 MHz, CDCl<sub>3</sub>) δ 158.0, 157.0, 154.6, 146.8, 144.8, 141.1, 134.0, 133.3, 130.2, 129.7, 129.5, 129.2, 129.0, 123.9, 123.2, 122.0, 119.5, 118.5, 116.4, 115.1, 112.4.

**Determination of the Structure of Compound 3aa**. To determine the structure of the cascade product, the compound **3aa** was obtained as a colorless crystal after the recrystallization from dichloromethane/hexanes. Based on single-crystal X-ray diffraction analysis, the structure of compound **3aa** was determined as 2,4-diphenyl-1-tosyl-1,2-dihydrozofuro[3,2-b]pyridine (see the [Supporting Information](#)). The CCDC number is 1911582. These details can be obtained free of charge via [www.ccdc.com.ac.uk/data\\_request/cif](http://www.ccdc.com.ac.uk/data_request/cif) from the Cambridge Crystallographic Data Center.

## ■ ASSOCIATED CONTENT

### Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: [10.1021/acs.joc.9b02512](https://doi.org/10.1021/acs.joc.9b02512).

Copies of <sup>1</sup>H, <sup>13</sup>C{<sup>1</sup>H} and <sup>19</sup>F{<sup>1</sup>H} spectra of all new compounds (PDF)

X-ray crystallography data **3aa** (CCDC 1911582) (CIF)

## ■ AUTHOR INFORMATION

### Corresponding Author

\*E-mail: [yzzhou@dicp.ac.cn](mailto:yzzhou@dicp.ac.cn).

### ORCID

Yong-Gui Zhou: 0000-0002-3321-5521

## Notes

The authors declare no competing financial interest.

## ■ ACKNOWLEDGMENTS

Financial support from the National Natural Science Foundation of China (21532006 and 21690074) and Chinese Academy of Sciences (XDB17020300 and QYZDJ-SSW-SLH035) is acknowledged.

## ■ REFERENCES

- (1) (a) Eicher, T., Hauptmann, S., Eds. *The Chemistry of Heterocycles: Structure, Reactions, Syntheses, and Applications*, 2nd ed.; Wiley VCH: Weinheim, Germany, 2003. (b) Joule, J. A., Mills, K., Eds.; *Heterocyclic Chemistry*, 5th ed.; Wiley-Blackwell: Chichester, U.K., 2010.
- (2) For reviews, see: (a) Tietze, L. F. Domino Reactions in Organic Synthesis. *Chem. Rev.* **1996**, *96*, 115–136. (b) Tietze, L. F.; Beifuss, U. Sequential Transformations in Organic Chemistry: A Synthetic Strategy with a Future. *Angew. Chem., Int. Ed.* **1993**, *32*, 131–163. (c) Nicolaou, K. C.; Montagnon, T.; Snyder, S. A. Tandem Reactions, Cascade Sequences, and Biomimetic Strategies in Total Synthesis. *Chem. Commun.* **2003**, 551–564. (d) Nicolaou, K. C.; Edmonds, D. J.; Bulger, P. G. Cascade Reactions in Total Synthesis. *Angew. Chem., Int. Ed.* **2006**, *45*, 7134–7186. (e) Lu, L.-Q.; Chen, J.-R.; Xiao, W.-J. Development of Cascade Reactions for the Concise Construction of Diverse Heterocyclic Architectures. *Acc. Chem. Res.* **2012**, *45*, 1278–1293. (f) Xu, P.-F., Wang, W., Eds. *Catalytic Cascade Reactions*; Wiley: Hoboken, 2014. (g) Smith, J. M.; Moreno, J.; Boal, B. W.; Garg, N. K. Cascade Reactions: A Driving Force in Akumamine Alkaloid Total Synthesis. *Angew. Chem., Int. Ed.* **2015**, *54*, 400–412. (h) Wang, Y.; Lu, H.; Xu, P.-F. Asymmetric Catalytic Cascade Reactions for Constructing Diverse Scaffolds and Complex Molecules. *Acc. Chem. Res.* **2015**, *48*, 1832–1844.
- (3) For selected examples see: (a) Beemelmans, C.; Reissig, H.-U. A Short Formal Total Synthesis of Strychnine with a Samarium Diodide Induced Cascade Reaction as the Key Step. *Angew. Chem., Int. Ed.* **2010**, *49*, 8021–8025. (b) Granger, B. A.; Jewett, I. T.; Butler, J. D.; Hua, B.; Knezevic, C. E.; Parkinson, E. I.; Hergenrother, P. J.; Martin, S. F. Synthesis of (±)-Actinophyllic Acid and Analogs: Applications of Cascade Reactions and Diverted Total Synthesis. *J. Am. Chem. Soc.* **2013**, *135*, 12984–12986. (c) Liu, J.; Ng, T.; Rui, Z.; Ad, O.; Zhang, W. Unusual Acetylation-Dependent Reaction Cascade in the Biosynthesis of the Pyrroloindole Drug Physostigmine. *Angew. Chem., Int. Ed.* **2014**, *53*, 136–139. (d) Yue, G.; Zhang, Y.; Fang, L.; Li, C.; Luo, T.; Yang, Z. Collective Synthesis of Cladiellins Based on the Gold-Catalyzed Cascade Reaction of 1,7-Diynes. *Angew. Chem., Int. Ed.* **2014**, *53*, 1837–1840.
- (4) (a) Eisner, U.; Kuthan, J. The Chemistry of Dihydropyridines. *Chem. Rev.* **1972**, *72*, 1–42. (b) Stout, D. M. Recent Advances in the Chemistry of Dihydropyridines. *Chem. Rev.* **1982**, *82*, 223–243. (c) Lavilla, R. Recent Developments in the Chemistry of Dihydropyridines. *J. Chem. Soc., Perkin Trans. 1* **2002**, 1141–1156. (d) Edraki, N.; Mehdipour, A. R.; Khoshneviszadeh, M.; Miri, R. Dihydropyridines: Evaluation of Their Current and Future Pharmacological Applications. *Drug Discovery Today* **2009**, *14*, 1058–1066.
- (5) For review, see: (a) Michael, J. P. Indolizidine and Quinolizidine Alkaloids. *Nat. Prod. Rep.* **2007**, *24*, 191–222. For selected examples, see: (b) Sales, M.; Charette, A. B. A Diels-Alder Approach to the Stereoselective Synthesis of 2,3,5,6-Tetra- and 2,3,4,5,6-Pentasubstituted Piperidines. *Org. Lett.* **2005**, *7*, 5773–5776. (c) Satoh, N.; Akiba, T.; Yokoshima, S.; Fukuyama, T. A Practical Synthesis of (-)-Oseltamivir. *Angew. Chem., Int. Ed.* **2007**, *46*, 5734–5736. (d) Sellstedt, M.; Dang, H. T.; Prasad, G. K.; Sauer, U.; Almqvist, F. Four-Component Assembly of Natural-Product-Like Ring-Fused Isoquinuclidines. *Eur. J. Org. Chem.* **2013**, *2013*, 7476–7479. (e) Duttwyler, S.; Chen, S.; Lu, C.; Mercado, B. Q.; Bergman, R. G.; Ellman, J. A. Regio- and Stereoselective 1,2-Dihydropyridine



Alkylation/Addition Sequence for the Synthesis of Piperidines with Quaternary Centers. *Angew. Chem., Int. Ed.* **2014**, *53*, 3877–3880. (f) Abas, H.; Frampton, C. S.; Spivey, A. C. Diels-Alder Reactions of  $\alpha$ -Amido Acrylates with *N*-Cbz-1,2-dihydropyridine and Cyclopentadiene. *J. Org. Chem.* **2016**, *81*, 9947–9956.

(6) (a) Koike, T.; Shinohara, Y.; Tanabe, M.; Takeuchi, N.; Tobinaga, S. A New and Efficient Synthesis of 2-Methyl-3-nitro-1,2-dihydropyridines by Heterocyclic Annulation Reactions of sec-Nitrodienamines with Acetaldehyde. *Chem. Pharm. Bull.* **1999**, *47*, 1246–1248. (b) Monguchi, D.; Majumdar, S.; Kawabata, T. Synthesis of Chiral 1,2-Dihydropyridines and 2,3,4-Trisubstituted Pyridines from  $\alpha$ -Amino Acids. *Heterocycles* **2006**, *68*, 2571–2578. (c) Wan, J.-P.; Gan, S.-F.; Sun, G.-L.; Pan, Y.-J. Novel Regioselectivity: Three-Component Cascade Synthesis of Unsymmetrical 1,4- and 1,2-Dihydropyridines. *J. Org. Chem.* **2009**, *74*, 2862–2865. (d) Yoshida, K.; Inokuma, T.; Takasu, K.; Takemoto, Y. Brønsted Acid-Thiourea Co-Catalysis: Asymmetric Synthesis of Functionalized 1,4-Dihydropyridines from  $\beta$ -Enamino Esters and  $\alpha,\beta$ -Unsaturated Aldehydes. *Synlett* **2010**, 1865–1869. (e) Xie, Y.-B.; Ye, S.-P.; Chen, W.-F.; Hu, Y.-L.; Li, D.-J.; Wang, L. Brønsted-Acid-Catalyzed Multicomponent One-Pot Reaction: Efficient Synthesis of Multisubstituted 1,2-Dihydropyridines. *Asian J. Org. Chem.* **2017**, *6*, 746–750.

(7) For review, see: (a) Bull, J. A.; Mousseau, J. J.; Pelletier, G.; Charette, A. B. Synthesis of Pyridine and Dihydropyridine Derivatives by Regio- and Stereoselective Addition to *N*-Activated Pyridines. *Chem. Rev.* **2012**, *112*, 2642–2713. For selected examples, see: (b) Foowler, F. W. Synthesis of 1,2- and 1,4-Dihydropyridines. *J. Org. Chem.* **1972**, *37*, 1321–1323. (c) Donohoe, T. J.; McRiner, A. J.; Helliwell, M.; Sheldrake, P. Use of Dissolving Metals in the Partial Reduction of Pyridines: Formation of 2-Alkyl-1,2-dihydropyridines. *J. Chem. Soc., Perkin Trans. 1* **2001**, 1435–1445. (d) Charette, A. B.; Grenon, M.; Lemire, A.; Pourashraf, M.; Martel, J. Practical and Highly Regio- and Stereoselective Synthesis of 2-Substituted Dihydropyridines and Piperidines: Application to the Synthesis of (-)-Coniine. *J. Am. Chem. Soc.* **2001**, *123*, 11829–11830. (e) Crotti, S.; Berti, F.; Pineschi, M. Copper-Catalyzed Perkin-Acyl-Mannich Reaction of Acetic Anhydride with Pyridine: Expedient Entry to Unconventional Piperidines. *Org. Lett.* **2011**, *13*, 5152–5155. (f) Chau, S. T.; Lutz, J. P.; Wu, K.; Doyle, A. G. Nickel-Catalyzed Enantioselective Arylation of Pyridinium Ions: Harnessing an Iminium Ion Activation Mode. *Angew. Chem., Int. Ed.* **2013**, *52*, 9153–9156.

(8) (a) Tanaka, K.; Fukase, K.; Katsumura, S. Exploring a Unique Reactivity of  $6\pi$ -Azaelectrocyclization to Enzyme Inhibition, Natural Products Synthesis, and Molecular Imaging: An Approach to Chemical Biology by Synthetic Chemists. *Synlett* **2011**, 2115–2139. (b) Silva, E. M. P.; Varandas, P. A. M.; Silva, A. M. S. Developments in the Synthesis of 1,2-Dihydropyridines. *Synthesis* **2013**, *45*, 3053–3089.

(9) (a) Rong, Z.-Q.; Wang, M.; Chow, C. H. E.; Zhao, Y. A Catalyst Enabled Diastereodivergent Aza-Diels-Alder Reaction: Complementarity of *N*-Heterocyclic Carbenes and Chiral Amines. *Chem. – Eur. J.* **2016**, *22*, 9483–9487. (b) Yang, L.-C.; Rong, Z.-Q.; Wang, Y.-N.; Tan, Z. Y.; Wang, M.; Zhao, Y. Construction of Nine-Membered Heterocycles through Palladium-Catalyzed Formal [5+4] Cycloaddition. *Angew. Chem., Int. Ed.* **2017**, *56*, 2927–2931. (c) Ni, H.; Tang, X.; Zheng, W.; Yao, W.; Ullah, N.; Lu, Y. Phosphine-catalyzed Enantioselective Formal [4+4] Annulation of  $\alpha,\beta$ -Unsaturated Imines and Allene Ketones: Construction of Eight-Membered Rings. *Angew. Chem., Int. Ed.* **2017**, *56*, 14222–14226. (d) Rong, Z.-Q.; Yang, L.-C.; Liu, S.; Yu, Z.; Wang, Y.-N.; Tan, Z. Y.; Huang, R.-Z.; Lan, Y.; Zhao, Y. Nine-Membered Benzofuran-Fused Heterocycles: Enantioselective Synthesis by Pd-Catalysis and Rearrangement via Transannular Bond Formation. *J. Am. Chem. Soc.* **2017**, *139*, 15304–15307. (e) Chen, J.; Huang, Y. Phosphine-Catalyzed Sequential [4+3] Domino Annulation/Allylic Alkylation Reaction of MBH Carbonates: Efficient Construction of Seven-Membered Heterocycles. *Org. Lett.* **2017**, *19*, 5609–5612. (f) Wang, Y.-N.; Yang, L.-C.; Rong, Z.-Q.; Liu, T.-L.; Liu, R.; Zhao, Y. Pd-Catalyzed Enantioselective [6+4] Cycloaddition

of Vinyl Oxetanes with Azadienes to Access Ten Membered Heterocycles. *Angew. Chem., Int. Ed.* **2018**, *57*, 1596–1600. (g) Gao, Z.-H.; Chen, K.-Q.; Zhang, Y.; Kong, L.-M.; Li, Y.; Ye, S. Enantioselective *N*-Heterocyclic Carbene Catalyzed Synthesis of Spirocyclic Oxindole-benzofuroazepinones. *J. Org. Chem.* **2018**, *83*, 15225–15235. (h) Gu, Z.; Wu, B.; Jiang, G.-F.; Zhou, Y.-G. Synthesis of Benzofuran-Fused 1,4-Dihydropyridines via Bifunctional Squaramidecatalyzed Formal [4+2] Cycloaddition of Azadienes with Malononitrile. *Chin. J. Chem.* **2018**, *36*, 1130–1134. (i) Gu, Z.; Zhou, J.; Jiang, G.-F.; Zhou, Y.-G. Synthesis of Chiral  $\gamma$ -Aminophosphonates through Organocatalytic Hydrophosphonylation of Azadienes with Phosphites. *Org. Chem. Front.* **2018**, *5*, 1148–1151. (j) Gu, Z.; Xie, J.-J.; Jiang, G.-F.; Zhou, Y.-G. Catalytic Asymmetric Conjugate Addition of Tritylthiol to Azadienes with a Bifunctional Organocatalyst. *Asian J. Org. Chem.* **2018**, *7*, 1561–1564. (k) Chen, J.; Jia, P.; Huang, Y. Divergent Domino Reactions of Sulfur Ylides: Access to Functionalized Six- and Seven-Membered Nitrogen-Heterocycles. *Org. Lett.* **2018**, *20*, 6715–6718. (l) Chen, K.-Q.; Gao, Z.-H.; Ye, S. Bifunctional *N*-Heterocyclic Carbene Catalyzed [3+4] Annulation of Enals with Azadienes: Enantioselective Synthesis of Benzofuroazepinones. *Org. Chem. Front.* **2019**, *6*, 405–409. (m) Wang, C.-S.; Li, T.-Z.; Cheng, Y.-C.; Zhou, J.; Mei, G.-J.; Shi, F. Catalytic Asymmetric [4+1] Cyclization of Benzofuran-Derived Azadienes with 3-Chlorooxindoles. *J. Org. Chem.* **2019**, *84*, 3214–3222. (n) Li, X.; Yan, J.; Qin, J.; Lin, S.; Chen, W.; Zhan, R.; Huang, H. Enantioselective Synthesis of Benzofuran-Fused *N*-Heterocycles via Chiral Squaramide Catalyzed [4+2] Cyclization of Azadienes with Azlactones. *J. Org. Chem.* **2019**, *84*, 8035–8045. (o) Zeng, R.; Shan, C.; Liu, M.; Jiang, K.; Ye, Y.; Liu, T.-Y.; Chen, Y.-C. [4+1+1] Annulations of  $\alpha$ -Bromo Carbonyls and 1-Azadienes toward Fused Benzoazaheterocycles. *Org. Lett.* **2019**, *21*, 2312–2316. (p) Lin, W.; Zhang, C.; Xu, W.; Cheng, Y.; Li, P.; Li, W. Organocatalytic Asymmetric Michael Addition of Rhodanines to Azadienes for Assembling of Sulfur-containing Tetrasubstituted Carbon Stereocenters. *Adv. Synth. Catal.* **2019**, *361*, 476–480. (q) Lin, W.; Lin, X.; Cheng, Y.; Chang, X.; Zhou, S.; Li, P.; Li, W. Organocatalytic Enantioselective Direct Vinylogous Michael Addition of  $\gamma$ -Substituted Deconjugate Butenolides to Azadienes. *Org. Chem. Front.* **2019**, *6*, 2452–2456. (r) Xie, H.-P.; Wu, B.; Wang, X.-W.; Zhou, Y.-G. Chiral Brønsted Acid-Catalyzed Conjugate Addition of Indoles to Azadienes: Enantioselective Synthesis of Hetero-Triarylmethanes. *Chin. J. Catal.* **2019**, *40*, 1566–1575. (s) Marques, A.-S.; Duhaill, T.; Marrot, J.; Chataigner, I.; Coeffard, V.; Vincent, G.; Moreau, X. A Fused Hexacyclic Ring System: Diastereoselective Polycyclization of 2,4-Dienals through an Interrupted iso-Nazarov Reaction. *Angew. Chem., Int. Ed.* **2019**, *58*, 9969–9973. (t) Fan, T.; Zhang, Z.-J.; Zhang, Y.-C.; Song, J. Construction of All-Carbon Quaternary Stereocenters via Sequential Photoactivation/Isothioureia Catalysis. *Org. Lett.* **2019**, *21*, 7897–7901.

(10) (a) Dedy, L. W.; Kaye, A. J.; Finlay, G. J.; Baguley, B. C.; Denny, A. W. Synthesis and Antitumor Properties of *N*-[2-(Dimethylamino)ethyl]carboxamide Derivatives of Fused Tetracyclic Quinolines and Quinoxalines: A New Class of Putative Topoisomerase Inhibitors. *J. Med. Chem.* **1997**, *40*, 2040–2046. (b) Voigt, B.; Meijer, L.; Lozach, O.; Schächtele, C.; Totzke, F.; Hilgeroth, A. Novel CDK Inhibition Profiles of Structurally Varied 1-Aza-9-oxafluorenes. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 823–825. (c) Khan, I. A.; Kulkarni, M. V.; Gopal, M.; Shahabuddin, M. S.; Sun, C. M. Synthesis and Biological Evaluation of Novel Angularly Fused Polycyclic Coumarins. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 3584–3587. (d) Kwon, H.-B.; Park, C.; Jeon, K.-H.; Lee, E.; Park, S.-E.; Jun, K.-Y.; Kadayat, T. M.; Thapa, P.; Karki, R.; Na, Y.; Park, M. S.; Rho, S. B.; Lee, E.-S.; Kwon, Y. A Series of Novel Terpyridine-Skeleton Molecule Derivatives Inhibit Tumor Growth and Metastasis by Targeting Topoisomerases. *J. Med. Chem.* **2015**, *58*, 1100–1122. (e) Thapa Magar, T. B.; Kadayat, T. M.; Lee, H.-J.; Park, S.; Bist, G.; Shrestha, A.; Kwon, Y.; Lee, E.-S. 2-Chlorophenyl-substituted Benzofuro[3,2-*b*]pyridines with Enhanced Topoisomerase Inhibitory Activity: The Role of the Chlorine Substituent. *Bioorg. Med. Chem. Lett.* **2017**, *27*, 3279–3283.

(11) Löser, R.; Chlupacova, M.; Marecek, A.; Opletalova, V.; Gütschow, M. Synthetic Studies Towards the Preparation of 2-Benzyl-2-hydroxybenzofuran-3(2H)-one, the Prototype of Naturally Occurring Hydrated Auronols. *Helv. Chim. Acta* **2004**, *87*, 2597–2601.

(12) (a) Ouellet, S. G.; Gauvreau, D.; Cameron, M.; Dolman, S.; Campeau, L.-C.; Hughes, G.; O'Shea, P. D.; Davies, I. W. Convergent, Fit-For-Purpose, Kilogram-Scale Synthesis of a 5-Lipoxygenase Inhibitor. *Org. Process Res. Dev.* **2012**, *16*, 214–219. (b) Tsou, H.-R.; MacEwan, G.; Birnberg, G.; Zhang, N.; Brooijmans, N.; Barza, L. T.; Hollander, I.; Kaloustian, S. A.; Yu, K. 4-Substituted-7-azaindoles Bearing a Ureidobenzofuranone Moiety as Potent and Selective, ATP-competitive Inhibitors of the Mammalian Target of Rapamycin (mTOR). *Bioorg. Med. Chem. Lett.* **2010**, *20*, 2259–2263.

(13) Wang, Z.; Li, S.; Yu, B.; Wu, H.; Wang, Y.; Sun, X. FeCl<sub>3</sub>·6H<sub>2</sub>O-Catalyzed Intramolecular Allylic Amination: Synthesis of Substituted Dihydroquinolines and Quinolines. *J. Org. Chem.* **2012**, *77*, 8615–8620.

(14) Thapa, P.; Jahng, Y.; Park, P.-H.; Jee, J.-G.; Kwon, Y.; Lee, E.-S. 2,4-Diaryl Benzofuro-[3,2-*b*]pyridine Derivatives: Design, Synthesis, and Evaluation of Topoisomerase Inhibitory Activity and Cytotoxicity. *Bull. Korean Chem. Soc.* **2013**, *34*, 3073–3082.

(15) Zhang, Z.-G.; Qian, H.; Longmire, J.; Zhang, X. Synthesis of Chiral Bisphosphines with Tunable Bite Angles and Their Applications in Asymmetric Hydrogenation of  $\beta$ -Ketoesters. *J. Org. Chem.* **2000**, *65*, 6223–6226.